Pgi27 the Burden of Non-Alcoholic Steatohepatitis (Nash) in the Eu5 Countries

Abstract

Objectives: NASH is a chronic disease that can progress to end-stage liver disease. This progression is particularly rapid in NASH patients with advanced liver fibrosis (stages F3-F4). This study estimated the disease burden and economic impact of NASH in the adult population of France, Germany, Italy, Spain and the UK.

Estimating the cost of illness of non‐alcoholic fatty liver disease in Bangladesh

“…As in the United States Japan, Europe, the United Kingdom, Iran, the Middle East, and other developed and developing countries, the burden of fatty liver certainly is increased in future. 4,7,[22][23][24][25][26][27][28][29][30] The study from France, Germany, Italy, Spain, the United Kingdom, and the United States in 2018 found that the mean total cost/per patient/year for NASH was €2763, €4917, and €5509 for direct medical, direct nonmedical, and indirect costs, respectively. 23 Another study included five countries in Europe that estimated total economic costs were €8548-19 546 M. Of these, health system costs were €619-1292 M, and total well-being costs were €41 536-90 379 M. 4 This study is similar to the current study in increasing cost with the severity of the disease.…”

“…As in the United States Japan, Europe, the United Kingdom, Iran, the Middle East, and other developed and developing countries, the burden of fatty liver certainly is increased in future. 4 , 7 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 The study from France, Germany, Italy, Spain, the United Kingdom, and the United States in 2018 found that the mean total cost/per patient/year for NASH was €2763, €4917, and €5509 for direct medical, direct nonmedical, and indirect costs, respectively. 23 …”